A novel SMARCA2-CREM fusion expending the molecular spectrum of salivary gland hyalinazing clear cell carcinoma beyond the FET genes
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu kazuistiky, časopisecké články
PubMed
36504225
DOI
10.1002/gcc.23114
Knihovny.cz E-zdroje
- Klíčová slova
- CREM, SMARCA2, hyalinizing clear cell carcinoma, salivary gland tumor,
- MeSH
- DNA-helikasy genetika MeSH
- exony MeSH
- fúzní onkogenní proteiny genetika metabolismus MeSH
- jaderné proteiny genetika metabolismus MeSH
- karcinom * genetika MeSH
- lidé MeSH
- modulátor elementu responzivního pro cyklický AMP genetika metabolismus MeSH
- nádory slinných žláz * genetika patologie MeSH
- protein EWS vázající RNA genetika MeSH
- slinné žlázy metabolismus MeSH
- transkripční faktory genetika metabolismus MeSH
- translokace genetická MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- CREM protein, human MeSH Prohlížeč
- DNA-helikasy MeSH
- fúzní onkogenní proteiny MeSH
- jaderné proteiny MeSH
- modulátor elementu responzivního pro cyklický AMP MeSH
- protein EWS vázající RNA MeSH
- SMARCA2 protein, human MeSH Prohlížeč
- SMARCA4 protein, human MeSH Prohlížeč
- transkripční faktory MeSH
Hyalinizing clear cell carcinoma (HCCC) is a rare salivary gland carcinoma with a generally indolent behavior, characterized by recurrent chromosomal translocation involving EWSR1 (22q12.2) leading to two fusion genes EWSR1::ATF1 or EWSR1::CREM. We report one case of HCCC with a novel SMARCA2::CREM fusion, identified by targeted RNA next generation sequencing by LD-RT-PCR, which has until now never been described in salivary glands. The exon 4 of SMARCA2 is fused to exon 5 of CREM. This fusion has been described previously in only one tumor, a central nervous system tumor (intracranial mesenchymal tumor) but not in other FET::CREB fused tumors. This fusion was confirmed by CREM break-apart FISH and reverse transcriptase polymerase chain reaction (RT-PCR). The tumor cells showed retained expression of INI1, SMARCA2, and SMARCA4 by immunohistochemistry. We compare its clinical, histopathological, immunophenotypic, genetic features with those previously described in HCCC, FET::CREB fusion-positive. Our results added data suggesting that different histomolecular tumor subtypes seem to be included within the terminology "HCCC, FET::CREB fusion-positive," and that further series of cases are needed to better characterize them.
Bioptic Laboratory Ltd Plzen Czech Republic
Department of Pathology Centre Henri Becquerel Rouen France
Department of Pathology Charles University Faculty of Medicine in Plzen Plzen Czech Republic
Zobrazit více v PubMed
WHO Classification of Tumours Editorial Board. Head and Neck Tumours [Internet]. International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 9). https://tumourclassification.iarc.who.int/chapters/52
Milchgrub S, Gnepp DR, Vuitch F, Delgado R, Albores-Saavedra J. Hyalinizing clear cell carcinoma of salivary gland. Am J Surg Pathol. 1994;18(1):74-82.
Desai A, Faquin WC, Iafrate AJ, Rivera MN, Jaquinet A, Troulis MJ. Clear cell carcinoma: a comprehensive literature review of 254 cases. Int J Oral Maxillofac Surg. 2022;51(6):705-712.
Antonescu CR, Katabi N, Zhang L, et al. EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Genes Chromosomes Cancer. 2011;50:559-570.
Chapman E, Skalova A, Ptakova N, et al. Molecular profiling of hyalinizing clear cell carcinomas revealed a subset of tumors harboring a novel EWSR1-CREM fusion. Am J Surg Pathol. 2018;42:1182-1189.
Thway K, Fisher C. Tumors with EWSR1-CREB1 and EWSR1-ATF1 fusions: the current status. Am J Surg Pathol. 2012;36(7):883-888.
Antonescu CR, Dal Cin P, Nafa K, et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2007;46:1051-1060.
Yoshida A, Wakai S, Ryo E, et al. Expanding the phenotypic spectrum of mesenchymal tumors harboring the EWSR1-CREM fusion. Am J Surg Pathol. 2019;43:1622-1630.
Antonescu CR, Tschernyavsky SJ, Woodruff JM, Jungbluth AA, Brennan MF, Ladanyi M. Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. J Mol Diagn. 2002;4:44-52.
Antonescu CR, Nafa K, Segal NH, Dal Cin P, Ladanyi M. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma-association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res. 2006;12:5356-5362.
Thway K, Nicholson AG, Lawson K, et al. Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion: a new tumor entity. Am J Surg Pathol. 2011;35:1722-1732.
Bilodeau EA, Weinreb I, Antonescu CR, et al. Clear cell odontogenic carcinomas show EWSR1 rearrangements: a novel finding and a biological link to salivary clear cell carcinomas. Am J Surg Pathol. 2013;37:1001-1005.
Breik O, Higginson J, Al-Ajami AK, Mohamed A, Martin T, Amel-Kashipaz R. Clear cell odontogenic carcinoma: first report of novel EWSR1-CREM fusion gene in case of long-term misdiagnosis. Head Neck Pathol. 2021;15:1391-1398.
Vogels R, Baumhoer D, van Gorp J, et al. Clear cell odontogenic carcinoma: occurrence of EWSR1-CREB1 as alternative fusion gene to EWSR1-ATF1. Head Neck Pathol. 2018;13:225-230.
Desmeules P, Joubert P, Zhang L, et al. A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1/FUS-ATF1 fusions. Am J Surg Pathol. 2017;41:980-988.
Argani P, Harvey I, Nielsen GP, et al. EWSR1/FUS-CREB fusions define a distinctive malignant epithelioid neoplasm with predilection for mesothelial-lined cavities. Mod Pathol. 2020;33:2233-2243.
Demetter P, Awada A, Aftimos P, et al. FUS::CREM-rearranged malignant epithelioid neoplasm mimicking neuroendocrine neoplasm of unknown primary. Histopathology. 2022;80(5):871-873.
Agaimy A, Stoehr R, Otto M, et al. Intra-abdominal EWSR1/FUS-CREM-rearranged malignant epithelioid neoplasms: two cases of an emerging aggressive entity with emphasis on misleading immunophenotype. Virchows Arch. 2022;480(2):481-486.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classifcation of tumors of the central nervous system: a summary. Neuro-Oncol. 2021;23:1231-1251. doi:10.1093/neuonc/noab106
Javaid S, Patton A, Tinoco G, Oghumu S, Iwenofu OH. Metastatic sporadic paraganglioma with EWSR1::CREM gene fusion: a unique molecular profile that expands the phenotypic diversity of the molecular landscape of the EWSR1::CREM gene fusion positive tumors. Genes Chromosomes Cancer. 2022;62:85-92. doi:10.1002/gcc.23094
Lanic MD, Le Loarer F, Rainville V, et al. Detection of sarcoma fusions by a next-generation sequencing based-ligation-dependent multiplex RT-PCR assay. Mod Pathol. 2022;35(5):649-663.
De Cesare D, Sassone-Corsi P. Transcriptional regulation by cyclic AMP-responsive factors. Prog Nucleic Acid Res Mol Biol. 2000;64:343-369.
Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12:141-151.
Tauziède-Espariat A, Pierron G, Guillemot D, et al. A novel SMARCA2-CREM fusion: expanding the molecular spectrum of intracranial mesenchymal tumors beyond the FET genes. Acta Neuropathol Commun. 2021;9(1):174.
Kaprio H, Heuser VD, Orte K, Tukiainen M, Leivo I, Gardberg M. Expression of transcription factor CREM in human tissues. J Histochem Cytochem. 2021;69(8):495-509.
Herpel E, Rieker RJ, Dienemann H, et al. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. Ann Diagn Pathol. 2017;26:47-51.
Perret R, Chalabreysse L, Watson S, et al. SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses. Am J Surg Pathol. 2019;43:455-465.
Wei S, Pei J, von Mehren M, Abraham JA, Patchefsky AS, Cooper HS. SMARCA2-NR4A3 is a novel fusion gene of extraskeletal myxoid chondrosarcoma identified by RNA next-generation sequencing. Genes Chromosomes Cancer. 2021;60(10):709-712.
Coccaro N, Brunetti C, Tota G, et al. A novel t(3;9)(q21.2; p24.3) associated with SMARCA2 and ZNF148 genes rearrangement in myelodysplastic syndrome. Leuk Lymphoma. 2018;59(4):996-999.
Twa DD, Mottok A, Chan FC, et al. Recurrent genomic rearrangements in primary testicular lymphoma. J Pathol. 2015;236(2):136-141.